Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim Limited

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

47 comunicati stampa

Guarda tutti i comunicati
29/04/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
27/04/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
15/04/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
13/04/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmaceutica
Medicina Salute Benessere
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
24/03/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmaceutica
Medicina Salute Benessere
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0